Using point of care testing and over the counter therapies to lessen the burden of allergic diseases
The prevalence of allergic diseases is increasing worldwide, and every year 400 million people suffer from allergic rhinitis. Allergic diseases are becoming an increasing public health concern and an economic burden. The costs for treating rhinitis in the US have doubled in 5 years to 11 billion US$.
Dr Neil Polwart, BBI Group Head of Mobile and founder of smartphone diagnostics specialists NovarumTM DX, discusses seven factors affecting the commercial success for companies embarking upon an mHealth strategy.
Immunoassays are one of the most widely used technology platforms in the detection of small chemical compounds, proteins, and microorganisms.
In a study published in 2017, several key stakeholders were interviewed to understand their views on what advantages can be gained from point of care (POC) diagnostics in rural primary healthcare (RHC) clinics and to identify some areas for further improvements.
In 2010, the World Health Organisation (WHO) recommended that all suspected cases of malaria be confirmed with a diagnostic test prior to treatment. Since this mandate rapid diagnostic tests (RDTs) have become the first-choice diagnostic tool for malaria despite test accuracy varying between brands, location and epidemiology settings.
The over the counter (OTC) marketplace is a particularly busy and congested retail space, with many big brands competing for position in a highly-regulated environment. Brand owners need to constantly explore new ways of attracting customers to retain and expand their market share and add value to their brand through innovation.
Mobile apps have already been deployed in field to help tackle the spread of infectious diseases, like Ebola, so can the mHealth technologies be applied to a virus such as Zika which is often relatively benign?
This article explores the mechanisms of antigen processing and how this contributes to T cell recognition of antigen and the regulation of the immune response.
Although lateral flow tests are simple and straightforward technology, there are multiple important steps to get right when developing a robust, reliable lateral flow test that will deliver the best results.
The economic costs of infectious diseases – especially HIV/AIDS and malaria – are significant. One of the key challenges within this market place is the accurate diagnosis of a disease to support early prevention and treatment. Discover BBI Solutions' capabilities including the production of over 600,000 tests for our customers in the infectious disease area last year.